التفاصيل البيبلوغرافية
| العنوان: |
Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma |
| المؤلفون: |
Fu Zhi-ying, Zhu Jun, Song Yu-qin, Liu Wei-ping, Ji Xin-qiang, Zhan Si-yan |
| المساهمون: |
Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, 100191, China., Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing 100142, China., Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Medical Record and Statistics, Peking University Cancer Hospital & Institute, Beijing 100142, China. |
| المصدر: |
PubMed |
| بيانات النشر: |
北京大学学报 医学版 |
| سنة النشر: |
2014 |
| المجموعة: |
Peking University Institutional Repository (PKU IR) / 北京大学机构知识库 |
| الوصف: |
To describe the clinical characteristics, overall survival as well as to evaluate the prognostic factors in Chinese diffuse large B cell lymphoma (DLBCL) patients.DLBCL patients who were initially diagnosed and treated in Peking University Cancer Hospital from January 1995 to December 2008 were identified and analyzed,retrospectively.The 5-year OS rates were estimated with Kaplan-Meier. Log-rank test was used to compare the survival curves of the different groups. The multivariate analysis of prognostic factors was conducted with Cox regression model, which included all statistically significant prognostic factors in the univariate analyses.A total of 525 DLBCL patients were included in this retrospective analysis, of whom, 294 were male and 231 female (male:female=1.27:1). The median age at the initial diagnosis was 55 (range 16-90) years, and 37.0% (n=194) were 60 years and above. Regarding the clinical staging at the initial diagnosis, 54 patients (10.3%) were diagnosed as Stage I of the disease, 152 (28.9%) as Stage II, 117 (22.3%) as Stage III and 202 (38.5%) as Stage IV. The "B symptoms" and increased serum LDH were presented in 206 (39.2%) and 192 (36.6%) patients, respectively. A total of 197 (37.5%) patients were treated with rituximab (R). The survival follow-up continued till 31 January 2014 with a median follow-up time of 77.5 (range: 0-205) months. A total of 267 patients (50.9%) died during the follow-up period. The medial overall survival (OS) time was 84 months, and 5-year OS rate was 52.3%. There were six statistically significant prognostic factors that were identified in both univariate and multivariate analyses: gender, Ann Arbor stage, B symptom, serum LDH, age at initial diagnosis and rituximab treatment. The relative risk (RR) of these prognostic factors in the multivariate analyses were: age > 60 years / ≤ 60 years=1.380 (95%CI 1.078-1.765), male / female=1.315 (95%CI 1.025-1.687), stage III/stage I=3.034 (95%CI 1.667-5.522), stage IV/I=3.748(95%CI 2.102-6.681), with B symptoms/without ... |
| نوع الوثيقة: |
journal/newspaper |
| اللغة: |
English |
| تدمد: |
1671-167X |
| Relation: |
Beijing da xue xue bao. Yi xue ban.2014,46,(3),405-11.; 652236; http://hdl.handle.net/20.500.11897/325988 |
| الاتاحة: |
https://hdl.handle.net/20.500.11897/325988 |
| رقم الانضمام: |
edsbas.75B9EAB4 |
| قاعدة البيانات: |
BASE |